Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers

Germline PIK3CA and AKT1 Mutations in Cowden and Cowden-like Syndromes

(2012) Mohammed S. Orloff et al.   AMERICAN JOURNAL OF HUMAN GENETICS

The p53 mRNA-Mdm2 Interaction Controls Mdm2 Nuclear Trafficking and Is Required for p53 Activation following DNA Damage

(2012) Madhavsai Gajjar et al.   CANCER CELL

p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast Cancer

(2012) James G. Jackson et al.   CANCER CELL

Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells

(2012) Mayu Yunokawa et al.   CANCER SCIENCE

Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer

(2012) Ivan Diaz-Padilla et al.   CANCER TREATMENT REVIEWS

Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence

(2012) Tongyuan Li et al.   CELL

p53 Opens the Mitochondrial Permeability Transition Pore to Trigger Necrosis

(2012) Angelina V. Vaseva et al.   CELL

HER2-Akt signaling in regulating COP9 signalsome subunit 6 and p53

(2012) Yuwen Xue et al.   CELL CYCLE

Preferential killing of p53-deficient cancer cells by reversine

(2012) Mohamed Jemaà et al.   CELL CYCLE

N-methylpurine DNA glycosylase inhibits p53-mediated cell cycle arrest and coordinates with p53 to determine sensitivity to alkylating agents

(2012) Shanshan Song et al.   CELL RESEARCH

Polymorphisms in base excision DNA repair genes and association with melanoma risk in a pilot study on Central-South Italian population

(2012) Concetta Santonocito et al.   CLINICA CHIMICA ACTA

RB-Pathway Disruption Is Associated with Improved Response to Neoadjuvant Chemotherapy in Breast Cancer

(2012) A. K. Witkiewicz et al.   CLINICAL CANCER RESEARCH

Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro

(2012) A. G. Patel et al.   CLINICAL CANCER RESEARCH

Effects of the combination of RAD001 and docetaxel on breast cancer stem cells

(2012) Xiaobei Zhang et al.   EUROPEAN JOURNAL OF CANCER

p63/p73 in the control of cell cycle and cell death

(2012) N. Allocati et al.   EXPERIMENTAL CELL RESEARCH

Temsirolimus: a safety and efficacy review

(2012) Ronald M. Bukowski   Expert Opinion On Drug Safety

Mutant p53: one name, many proteins

(2012) W. A. Freed-Pastor et al.   GENES & DEVELOPMENT

BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer

(2012) Rebecca Byler Dann et al.   GYNECOLOGIC ONCOLOGY

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

(2012) Thomas Bachelot et al.   JOURNAL OF CLINICAL ONCOLOGY

BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group

(2012) Kathryn Alsop et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

(2012) Sören Lehmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

(2012) Kimberly L. Blackwell et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

(2012) Isabelle Ray-Coquard et al.   LANCET ONCOLOGY

The DNA damage response and cancer therapy

(2012) Christopher J. Lord et al.   NATURE

De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes

(2012) Jean-Baptiste Rivière et al.   NATURE GENETICS

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

(2012) Jonathan Ledermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

(2012) Yasir H. Ibrahim et al.   Cancer Discovery

Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer

(2012) Ashish Juvekar et al.   Cancer Discovery

Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients

(2011) P. M. L. H. Vencken et al.   ANNALS OF ONCOLOGY

Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations

(2011) Soley Bayraktar et al.   BREAST CANCER RESEARCH AND TREATMENT

PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy

(2011) Pawel Domagala et al.   BREAST CANCER RESEARCH AND TREATMENT

The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers

(2011) Mieke Kriege et al.   CANCER

The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians

(2011) Stian Knappskog et al.   CANCER CELL

Gene expression signature of TP53 but not its mutation status predicts response to sequential paclitaxel and 5-FU/epirubicin/cyclophosphamide in human breast cancer

(2011) Kazuteru Oshima et al.   CANCER LETTERS

Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression

(2011) Colleen A. Brady et al.   CELL

A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?

(2011) Leonardo Salmena et al.   CELL

Mutant p53 protein localized in the cytoplasm inhibits autophagy

(2011) Eugenia Morselli et al.   CELL CYCLE

Synthetic lethality of PARP inhibition in cancers lackingBRCA1andBRCA2mutations

(2011) Konstantin J. Dedes et al.   CELL CYCLE

Alterations of the retinoblastoma gene in metastatic breast cancer

(2011) Elisabet Ognedal Berge et al.   CLINICAL & EXPERIMENTAL METASTASIS

Fanconi anaemia: from a monogenic disease to sporadic cancer

(2011) Antonio Valeri et al.   Clinical & Translational Oncology

Coordinated action of the Fanconi anemia and ataxia telangiectasia pathways in response to oxidative damage

(2011) Pau Castillo et al.   DNA REPAIR

Down-regulation ofBRCA1expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers

(2011) Amandine I. Garcia et al.   EMBO Molecular Medicine

SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer

(2011) Stian Knappskog et al.   EUROPEAN JOURNAL OF CANCER

RB1 mutations and second primary malignancies after hereditary retinoblastoma

(2011) Charlotte J. Dommering et al.   Familial Cancer

Functional and physical interaction between the mismatch repair and FA-BRCA pathways

(2011) Stacy A. Williams et al.   HUMAN MOLECULAR GENETICS

BRCA1 is required for hMLH1 stabilization following doxorubicin-induced DNA damage

(2011) Francesco Romeo et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer

(2011) Da Yang et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype

(2011) Romain Micol et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Distinct Roles of FANCO/RAD51C Protein in DNA Damage Signaling and Repair

(2011) Kumar Somyajit et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Insight into the heterogeneity of breast cancer through next-generation sequencing

(2011) Hege G. Russnes et al.   JOURNAL OF CLINICAL INVESTIGATION

Cytoplasmic Poly(Adenosine Diphosphate–Ribose) Polymerase Expression Is Predictive and Prognostic in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy

(2011) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Response to Neoadjuvant Systemic Therapy for Breast Cancer inBRCAMutation Carriers and Noncarriers: A Single-Institution Experience

(2011) Banu Arun et al.   JOURNAL OF CLINICAL ONCOLOGY

Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas

(2011) Barbara Norquist et al.   JOURNAL OF CLINICAL ONCOLOGY

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial

(2011) Hervé Bonnefoi et al.   LANCET ONCOLOGY

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

(2011) Karen A Gelmon et al.   LANCET ONCOLOGY

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Germline mutations in RAD51D confer susceptibility to ovarian cancer

(2011) Chey Loveday et al.   NATURE GENETICS

Mutations in BRIP1 confer high risk of ovarian cancer

(2011) Thorunn Rafnar et al.   NATURE GENETICS

Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells

(2011) Barthelemy Diouf et al.   NATURE MEDICINE

Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer

(2011) Joyce O'Shaughnessy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism

(2011) S Al-Bahlani et al.   ONCOGENE

Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer

(2011) J. Baselga   ONCOLOGIST

Role of p53 Serine 46 in p53 Target Gene Regulation

(2011) Leonie Smeenk et al.   PLoS One

Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel

(2011) Ranjan Chrisanthar et al.   PLoS One

Two-phase dynamics of p53 in the DNA damage response

(2011) X.-P. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

(2011) T. Walsh et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1

(2010) Ramesh M. Ray et al.   APOPTOSIS

Lack of association between ATM C.1066-6T > G mutation and breast cancer risk: a meta-analysis of 8,831 cases and 4,957 controls

(2010) Hong Ding et al.   BREAST CANCER RESEARCH AND TREATMENT

Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer

(2010) Mohammed A. Aleskandarany et al.   BREAST CANCER RESEARCH AND TREATMENT

Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age

(2010) Dorina M. van der Kolk et al.   BREAST CANCER RESEARCH AND TREATMENT

No significant association between the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis of 21 studies involving 24,063 subjects

(2010) Yanlei Ma et al.   BREAST CANCER RESEARCH AND TREATMENT

Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin

(2010) K. Hastak et al.   CANCER RESEARCH

Rb-dependent cellular senescence, multinucleation and susceptibility to oncogenic transformation through PKC scaffolding by SSeCKS/AKAP12

(2010) Shin Akakura et al.   CELL CYCLE

Weak p53 permits senescence during cell cycle arrest

(2010) Olga V. Leontieva et al.   CELL CYCLE

Regulation of Excision Repair Cross-Complementation Group 1 by Snail Contributes to Cisplatin Resistance in Head and Neck Cancer

(2010) D. S.-S. Hsu et al.   CLINICAL CANCER RESEARCH

ERCC1 (excision repair cross-complementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO stage 2B uterine cervix cancer

(2010) Jong-Sup Park et al.   GYNECOLOGIC ONCOLOGY

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

(2010) Daniel P. Silver et al.   JOURNAL OF CLINICAL ONCOLOGY

Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer

(2010) Bryan T.J. Hennessy et al.   JOURNAL OF CLINICAL ONCOLOGY

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval

(2010) Peter C. Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

TP53Mutation and Survival in Chronic Lymphocytic Leukemia

(2010) Thorsten Zenz et al.   JOURNAL OF CLINICAL ONCOLOGY

Reply to K. Tay et al

(2010) Marita Ziepert et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers

(2010) Elisabet Berge et al.   Molecular Cancer

Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer

(2010) M. C. Villarroel et al.   MOLECULAR CANCER THERAPEUTICS

miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP Inhibitors

(2010) Patryk Moskwa et al.   MOLECULAR CELL

Molecular basis for therapy resistance

(2010) Per E. Lønning   Molecular Oncology

A coding-independent function of gene and pseudogene mRNAs regulates tumour biology

(2010) Laura Poliseno et al.   NATURE

Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene

(2010) Alfons Meindl et al.   NATURE GENETICS

Synthetic lethal approaches to breast cancer therapy

(2010) Farah L. Rehman et al.   Nature Reviews Clinical Oncology

Cyclophosphamide Dose Intensification May Circumvent Anthracycline Resistance of p53 Mutant Breast Cancers

(2010) J. Lehmann-Che et al.   ONCOLOGIST

Rare, Evolutionarily Unlikely Missense Substitutions in ATM Confer Increased Risk of Breast Cancer

(2009) Sean V. Tavtigian et al.   AMERICAN JOURNAL OF HUMAN GENETICS

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer

(2009) SR Young et al.   BMC CANCER

Proapoptotic Function of the Retinoblastoma Tumor Suppressor Protein

(2009) Alessandra Ianari et al.   CANCER CELL

PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain

(2009) Jeremy M.R. Lambert et al.   CANCER CELL

Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes

(2009) E. A. Rakha et al.   CLINICAL CANCER RESEARCH

Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications

(2009) HT Lynch et al.   CLINICAL GENETICS

Human DNA damage response and repair deficiency syndromes: Linking genomic instability and cell cycle checkpoint proficiency

(2009) Claudia Kerzendorfer et al.   DNA REPAIR

Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair geneMSH2

(2009) Sarah A. Martin et al.   EMBO Molecular Medicine

Methylation not a frequent “second hit” in tumors with germline BRCA mutations

(2009) Amy M. Dworkin et al.   Familial Cancer

Regulation of the p53 transcriptional response by structurally diverse core promoters

(2009) J. M. Morachis et al.   GENES & DEVELOPMENT

Reply to C. Badoual et al

(2009) Paul Salama et al.   JOURNAL OF CLINICAL ONCOLOGY

Sensitivity to First-Line Chemotherapy for Metastatic Breast Cancer inBRCA1andBRCA2Mutation Carriers

(2009) Mieke Kriege et al.   JOURNAL OF CLINICAL ONCOLOGY

Microsatellite Instability, Mismatch Repair Deficiency, andBRAFMutation in Treatment-Resistant Germ Cell Tumors

(2009) Friedemann Honecker et al.   JOURNAL OF CLINICAL ONCOLOGY

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

(2009) Stephen Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

(2009) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial

(2009) Judith Hugh et al.   JOURNAL OF CLINICAL ONCOLOGY

Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy

(2009) Tomasz Byrski et al.   JOURNAL OF CLINICAL ONCOLOGY

The p53-mediated sensitivity of cancer cells to chemotherapeutic agents is conditioned by the status of the retinoblastoma protein

(2009) Massimo Derenzini et al.   JOURNAL OF PATHOLOGY

Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy

(2009) F. P. O'Malley et al.   JNCI-Journal of the National Cancer Institute

Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways

(2009) X. Liu et al.   MOLECULAR CANCER RESEARCH

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy

(2009) J Yang et al.   ONCOGENE

Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene

(2009) G. S. Atwal et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Platinum-based chemotherapy in triple-negative breast cancer

(2008) B. Sirohi et al.   ANNALS OF ONCOLOGY

miR-34a as part of the resistance network in chronic lymphocytic leukemia

(2008) T. Zenz et al.   BLOOD

Penetrance estimates for BRCA1 and BRCA2based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family

(2008) D Gareth Evans et al.   BMC CANCER

Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum Resistance

(2008) E. M. Swisher et al.   CANCER RESEARCH

The Fanconi anaemia/BRCA pathway and cancer susceptibility. Searching for new therapeutic targets

(2008) M. José García et al.   Clinical & Translational Oncology

Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

(2008) M. C.U. Cheang et al.   CLINICAL CANCER RESEARCH

DNA repair deficiency as a therapeutic target in cancer

(2008) Sarah A Martin et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

TAp73 knockout shows genomic instability with infertility and tumor suppressor functions

(2008) R. Tomasini et al.   GENES & DEVELOPMENT

Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial

(2008) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations

(2008) David S.P. Tan et al.   JOURNAL OF CLINICAL ONCOLOGY

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY

Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non–small cell lung cancer

(2008) Daniela Kandioler et al.   JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

MDM2 Gene Amplification Is Correlated to Tumor Progression but not to the Presence of SNP309 or TP53 Mutational Status in Primary Colorectal Cancers

(2008) A. Forslund et al.   MOLECULAR CANCER RESEARCH

p53-dependent global nucleotide excision repair of cisplatin-induced intrastrand cross links in human cells

(2008) S. Bhana et al.   MUTAGENESIS

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

(2008) Wataru Sakai et al.   NATURE

Resistance to therapy caused by intragenic deletion in BRCA2

(2008) Stacey L. Edwards et al.   NATURE

AKT1 E17K in human solid tumours

(2008) F E Bleeker et al.   ONCOGENE

CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer

(2008) Ranjan Chrisanthar et al.   PLoS One

Taxanes, microtubules and chemoresistant breast cancer

(2007) Barbara T. McGrogan et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER